Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics (NASDAQ: FATE), a clinical-stage biopharmaceutical company focused on iPSC-derived cellular immunotherapies for cancer and autoimmune diseases, has announced new employee inducement awards. The company granted restricted stock units (RSUs) for 32,200 shares of common stock to two newly-hired non-executive employees on April 1, 2025.
The grants, approved by the Compensation Committee under the Company's Amended and Restated Inducement Equity Plan, will vest over four years, with 25% vesting annually on each grant date anniversary. The awards comply with Nasdaq Listing Rule 5635(c)(4) and are contingent on continuous employment through each vesting date.
Fate Therapeutics (NASDAQ: FATE), un'azienda biofarmaceutica in fase clinica specializzata in immunoterapie cellulari derivate da iPSC per il cancro e le malattie autoimmuni, ha annunciato nuovi premi di incentivazione per i dipendenti. L'azienda ha concesso unità di azioni vincolate (RSU) per 32.200 azioni di azioni ordinarie a due nuovi dipendenti non esecutivi il 1° aprile 2025.
I premi, approvati dal Comitato per la Compensazione nell'ambito del Piano di Incentivazione Azionaria Modificato e Riformulato della Società, matureranno in quattro anni, con il 25% che matura annualmente in occasione dell'anniversario di ciascuna data di concessione. I premi sono conformi alla Regola di Quotazione Nasdaq 5635(c)(4) e sono subordinati all'impiego continuativo fino a ciascuna data di maturazione.
Fate Therapeutics (NASDAQ: FATE), una empresa biofarmacéutica en etapa clínica centrada en inmunoterapias celulares derivadas de iPSC para el cáncer y enfermedades autoinmunes, ha anunciado nuevos premios de incentivo para empleados. La empresa otorgó unidades de acciones restringidas (RSU) por 32,200 acciones de acciones ordinarias a dos nuevos empleados no ejecutivos el 1 de abril de 2025.
Las concesiones, aprobadas por el Comité de Compensación bajo el Plan de Incentivo de Capital Modificado y Reformulado de la Compañía, se consolidarán en cuatro años, con el 25% consolidándose anualmente en el aniversario de cada fecha de concesión. Los premios cumplen con la Regla de Cotización Nasdaq 5635(c)(4) y están sujetos a empleo continuo hasta cada fecha de consolidación.
Fate Therapeutics (NASDAQ: FATE), 암 및 자가면역 질환을 위한 iPSC 유래 세포 면역 요법에 중점을 둔 임상 단계의 생명공학 회사가 새로운 직원 유인 보상을 발표했습니다. 이 회사는 2025년 4월 1일에 두 명의 신규 비임원 직원에게 32,200주의 보통주에 대한 제한 주식 단위(RSU)를 부여했습니다.
이 보상은 회사의 수정 및 재작성된 유인 주식 계획에 따라 보상 위원회에 의해 승인되었으며, 4년에 걸쳐 분할 지급됩니다, 각 부여일 기념일마다 25%가 매년 지급됩니다. 이 보상은 나스닥 상장 규칙 5635(c)(4)를 준수하며, 각 분할 지급일까지 지속적인 고용에 따라 달라집니다.
Fate Therapeutics (NASDAQ: FATE), une entreprise biopharmaceutique en phase clinique axée sur les immunothérapies cellulaires dérivées de l'iPSC pour le cancer et les maladies auto-immunes, a annoncé de nouvelles récompenses d'incitation pour les employés. L'entreprise a accordé des unités d'actions restreintes (RSU) pour 32 200 actions de capital ordinaire à deux nouveaux employés non exécutifs le 1er avril 2025.
Les attributions, approuvées par le Comité de Rémunération dans le cadre du Plan d'Incentive en Actions Modifié et Révisé de la Société, seront acquises sur quatre ans, avec 25 % acquises chaque année à l'anniversaire de chaque date d'attribution. Les récompenses sont conformes à la Règle de Cotation Nasdaq 5635(c)(4) et sont conditionnelles à un emploi continu jusqu'à chaque date d'acquisition.
Fate Therapeutics (NASDAQ: FATE), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf iPSC-abgeleitete zelluläre Immuntherapien für Krebs und Autoimmunerkrankungen konzentriert, hat neue Anreizprämien für Mitarbeiter angekündigt. Das Unternehmen hat am 1. April 2025 32.200 Aktien von Stammaktien in Form von eingeschränkten Aktieneinheiten (RSUs) an zwei neu eingestellte nicht-executive Mitarbeiter vergeben.
Die Zuwendungen, die vom Vergütungsausschuss im Rahmen des überarbeiteten und neu gefassten Anreiz-Eigenkapitalplans des Unternehmens genehmigt wurden, werden über vier Jahre fällig, wobei 25% jährlich am Jahrestag des jeweiligen Zuwendungsdatums fällig werden. Die Prämien entsprechen der Nasdaq-Listing-Regel 5635(c)(4) und sind von einer kontinuierlichen Beschäftigung bis zu jedem Fälligkeitstermin abhängig.
- None.
- None.
SAN DIEGO, April 02, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on April 1, 2025 the Company granted restricted stock units (RSUs) representing 32,200 shares of its common stock to two newly-hired non-executive employees. The grants were approved by the Compensation Committee of the Company’s Board of Directors and granted under the Company’s Amended and Restated Inducement Equity Plan as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with
About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived natural killer (NK) cell and T-cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
Contact:
Christina Tartaglia
Precision AQ
212.362.1200
christina.tartaglia@precisionaq.com
FAQ
How many shares of FATE stock were granted as RSUs in the April 2025 inducement awards?
What is the vesting schedule for FATE's April 2025 RSU inducement awards?
Under which regulatory rule were FATE's April 2025 inducement awards granted?
Who approved the FATE inducement equity awards in April 2025?
